-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, June 29 News On June 28, the National Health Commission issued a message to guide medical institutions to scientifically set management indicators for the clinical application of anti-tumor drugs and improve the level of reasonable clinical application of anti-tumor drugs.
The National Health and Health Commission organized the formulation and Released the "Management Indicators for the Rational Application of Anti-tumor Drugs (2021 Edition)"
.
Reads as follows:
National Health Health Committee General Office on the issuance of anti -tumor clinical drug rational use of management indicators (2021 edition) notice
AXA organized medicine Han [2021] 336
provinces, autonomous regions and municipalities and Xinjiang Production and Construction Corps health committee: for the Implement the "Administrative Measures for the Clinical Application of Anti-tumor Drugs (Trial)" (Guowei Medical Letter [2020] No.
487), guide medical institutions to scientifically set management indicators for the clinical application of anti-tumor drugs, and improve the level of reasonable clinical application of anti-tumor drugs.
The Commission organized the formulation of the "Management Indicators for the Rational Application of Anti-tumor Drugs (2021 Edition)"
.
Now it is issued to you, please refer to the implementation
.
Attachment: Management Indicators for the Rational Application of Anti-tumor Drugs (2021 Edition)
General Office of the National Health Commission June 17, 2021
The National Health and Health Commission organized the formulation and Released the "Management Indicators for the Rational Application of Anti-tumor Drugs (2021 Edition)"
.
Reads as follows:
National Health Health Committee General Office on the issuance of anti -tumor clinical drug rational use of management indicators (2021 edition) notice
AXA organized medicine Han [2021] 336
provinces, autonomous regions and municipalities and Xinjiang Production and Construction Corps health committee: for the Implement the "Administrative Measures for the Clinical Application of Anti-tumor Drugs (Trial)" (Guowei Medical Letter [2020] No.
487), guide medical institutions to scientifically set management indicators for the clinical application of anti-tumor drugs, and improve the level of reasonable clinical application of anti-tumor drugs.
The Commission organized the formulation of the "Management Indicators for the Rational Application of Anti-tumor Drugs (2021 Edition)"
.
Now it is issued to you, please refer to the implementation
.
Attachment: Management Indicators for the Rational Application of Anti-tumor Drugs (2021 Edition)
General Office of the National Health Commission June 17, 2021
![1-METHYL-4-[5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABORALAN-2-YL)PYRIDINE-2-YL]PIPERAZINE](https://file.echemi.com/fileManage/upload/goodpicture/20210822/m20210822160345712.jpg)
